Department of Medical Oncology, University of Turin Medical School, Institute for Cancer Research and Treatment (IRCC), Candiolo, Italy.
Crit Rev Oncol Hematol. 2013 Feb;85(2):136-48. doi: 10.1016/j.critrevonc.2012.06.006. Epub 2012 Jul 17.
Biliary tract carcinomas (BTC) are a group of tumours arising from the epithelial cells of intra- and extra-hepatic biliaryducts and the gallbladder, characterised by a poor prognosis. Surgery is the only curative procedure, but the risk of recurrence is high and furthermore, the majority of patients present with unresectable disease at the time of diagnosis. Systemic therapy is the mainstay of treatment for patients who present recurrent or metastatic disease. Progress has been made in the last decade to identify the most effective chemotherapy regimens, with the recent recommendation of the combination of gemcitabine-cisplatin as the standard schedule. Comprehension of the molecular basis of cholangiocarcinogenesis and tumour progression has recently led to the experimentation of targeted therapies in patients with BTC, demonstrating promising results. In this review we will discuss the clinical experience with systemic treatment for BTC, focusing on future directions with targeted therapies.
胆管癌（BTC）是一组源自肝内外胆管和胆囊上皮细胞的肿瘤，其预后较差。手术是唯一的治愈方法，但复发风险很高，此外，大多数患者在诊断时已患有不可切除的疾病。对于出现复发或转移性疾病的患者，系统治疗是主要的治疗方法。在过去十年中，已经取得了进展，以确定最有效的化疗方案，最近推荐使用吉西他滨-顺铂联合方案作为标准方案。对胆管癌发生和肿瘤进展的分子基础的理解最近导致了针对 BTC 患者的靶向治疗的实验，显示出有前途的结果。在这篇综述中，我们将讨论针对 BTC 的系统治疗的临床经验，重点是靶向治疗的未来方向。
